Warwick's first drug like riluzole reduces the cost of ALS patients by more than 50%

Overnight, the "ALS ice bucket challenge" campaign was launched to appeal to the public to pay attention to ALS (amyotrophic lateral sclerosis, commonly known as "progressive frostbite") as a rare disease and raise money for patients Riluzole is the only ALS drug approved by FDA in the United States It has a certain effect on ALS patients with bulbar palsy or limb paralysis as the first symptom The drug was originally developed by Sanofi Warwick was the first one in China to apply for registration of riluzole in 2002, which was approved by CFDA for the first copy In 2005, it was produced and listed by lunanbert Pharmaceutical Co., Ltd under the trade name of "xieyili" Compared with the original imported products, the cost of ALS patients was reduced by more than 50% The cost of research and development of rare disease drugs is high According to the data, the average cost of research and development of an innovative drug is about 1.3 billion US dollars, which takes about 10-15 years However, the market of orphan drugs is very limited, and the R & D is difficult and risky If there is no policy incentive, the enterprise has no enthusiasm As a leading enterprise focusing on new drug research and development in China, Huawei pharmaceutical adheres to the concept of scientific and technological innovation and serving the public It has long paid attention to rare disease treatment drugs, and has developed and applied for a variety of rare disease treatment drugs, such as "fengomod hydrochloride capsule", the first national class III new drug approved for clinical use in 2014 About Huawei pharmaceutical Nanjing Huawei Pharmaceutical Technology Development Co., Ltd (Huawei pharmaceutical) was founded in 2000 It is a high-tech enterprise specializing in drug discovery, research and technical services It is a certified high-tech enterprise in Jiangsu Province (2012), excellent enterprise in Jiangsu Province (2014), excellent private enterprise in Jiangsu Province (2013) and private technology enterprise in Jiangsu Province (2012) Huawei pharmaceutical won the 8th Qingke "2013 top 50 enterprises with the most investment value in China", won the highest award in China's technical service field - "Golden Bridge Award" of China Technology Market Association for two consecutive times (the fifth / sixth), and won the support of several provincial and municipal innovation / development funds Warwick Pharma has two wholly-owned subsidiaries, Nanjing weinord Pharma Technology Co., Ltd (weinord Pharma) and Jiangsu Lihua Biotechnology Co., Ltd (Lihua bio) Weinord Pharma is mainly engaged in the production and sales of customized synthesis, CMO, API and related intermediates; Lihua bio is mainly engaged in clinical cro and import registration services of drugs / devices As for ALS, it is also called motor neuron disease (MND) The latter name is commonly used in England, Charcot disease in France and Lou Gehrig disease in America In China, amyotrophic lateral sclerosis and motor neuron disease are usually mixed It is caused by the injury of the upper and lower motor neurons, resulting in the gradual weakness and atrophy of the muscles including the bulbar (the so-called bulbar, which means the part of muscles dominated by the medulla oblongata), limbs, trunk, chest and abdomen The chemical name of riluzole tablets is 2-amino-6-trifluoromethoxybenzothiazole This product is white or almost white It can prolong the survival period and / or delay the tracheotomy in the treatment of ALS patients The chemical name of riluzole is 2-amino-6-trifluoromethoxybenzothiazole This product is white or similar white It can prolong the survival period and / or delay the tracheotomy in the treatment of ALS patients [trade name] Rilutek, lirutai [alias] pk-26124, rp-54274 [category] treatment drug of motor neuron disease, glutamate antagonist [chemical name] 2-aminotrifluoromethoxybenzothiazole [CAS] 1744-22-5 [development unit] French Aventis pharmaceutical company [character] crystal, ethanol water (1:1) mp119 ℃ LD50 mice (mg / kg) 46 (IP); 67 (oral) [patent] ep558861